SavedAdd your journal

Journals / Turkish archives of pediatrics (Online) / 2022 / Cilt: 57 - Sayı: 1

Inhaled Pharmacotherapy for Neonates: A Narrative Review

Gustavo M ROCHA
Pages
5–17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A summary of the main and most recent published studies on each of these inhaled pharmacological agents is also presented.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The inhaled route for drug administration in neonates offers several advantages over the systemic routes, since it delivers medications directly to the diseased organ, enabling higher doses locally with less systemic toxicity.
📊
Key Findings & Data:Respiratory drugs can be administered in both ventilated and non-ventilated term and preterm infants.
💡
Conclusion & Impact:A summary of the main and most recent published studies on each of these inhaled pharmacological agents is also presented.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

The inhaled route for drug administration in neonates offers several advantages over the systemic routes, since it delivers medications directly to the diseased organ, enabling higher doses locally with less systemic toxicity. Respiratory drugs can be administered in both ventilated and non-ventilated term and preterm infants. This review was carried out using selected literature, with a focus on the most used inhaled pharmacological agents in neonatal care, summarizing, with levels of evidence (LoE), their indications, doses, administration schedules, and main adverse effects. Information is given on several inhaled drugs, namely albuterol, budesonide, ipratropium bromide, sodium cromoglycate, racemic epinephrine, nitric oxide, treprostinil, iloprost, epoprostenol, colistin, rhDNase, hypertonic saline, and calfactant. A summary of the main and most recent published studies on each of these inhaled pharmacological agents is also presented.

🔖

Cite This Article

ROCHA, G. M. (2022). Inhaled Pharmacotherapy for Neonates: A Narrative Review. Turkish archives of pediatrics (Online), Cilt: 57 - Sayı: 1, 5–17. https://ajindex.com/articles/418280

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Gallacher DJ, Hart K, Kotecha S. Common respiratory conditions of the newborn. Breathe (Sheff). 2016
  2. 12(1):30-42. [CrossRef] 2. Stocks J. Respiratory physiology during early life. Monaldi Arch Chest Dis. 1999
  3. 54(4):358-364. 3. Rocha G, Soares P, Gonçalves A et al. Respiratory care for the ventilated neonate. Can Respir J. 2018
  4. 7472964. [CrossRef] 4. Flôr-de-Lima F, Rocha G, Guimarães H. Impact of changes in perinatal care on neonatal respiratory outcome and survival of preterm newborns: an overview of 15 years. Crit Care Res Pract. 2012
  5. 643246. [CrossRef] 5. Azevedo A, Flôr-de-Lima F, Rocha G, Rodrigues C, Guimarães H. Impact of changes in perinatal care on bronchopulmonary dysplasia: an overview of the last two decades. J Ped Neonatal Ind Med. 2017
  6. 6(2):e060208. 6. De Luca D, Cogo P, Zecca E et al. Intrapulmonary drug administration in neonatal and paediatric critical care: a comprehensive review. Eur Respir J. 2011
  7. 37(3):678-689. [CrossRef] 7. Cole CH, Colton T, Shah BL et al. Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia. N Engl J Med. 1999
  8. 340(13):1005-1010. [CrossRef] 8. Sood BG, Delaney-Black V, Aranda JV, Shankaran S. Aerosolized PGE1: a selective pulmonary vasodilator in neonatal hypoxemic respiratory failure results of a phase I/II open label clinical trial. Pediatr Res. 2004
  9. 56(4):579-585. [CrossRef] 9. Armangil D, Yurdakök M, Korkmaz A, Yiğit S, Tekinalp G. Inhaled beta-2 agonist salbutamol for the treatment of transient tachypnea of the newborn. J Pediatr. 2011
  10. 159(3):398-403.e1. [CrossRef] 10. Shah V, Ohlsson A, Halliday HL, Dunn MS. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev. 2007
  11. CD002057. 11. Berggren E, Liljedahl M, Winbladh B et al. Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome. Acta Paediatr. 2000
  12. 89(4):460-464. [CrossRef] 12. Ruggiero A, Ariano A, Triarico S et al. Neonatal pharmacology and clinical implications. Drugs Context. 2019
  13. 212608. [CrossRef] 13. Bianco F, Salomone F, Milesi I. et al. Aerosol drug delivery to spontaneously-breathing preterm neonates: lessons learned. Respir Res. 2021 Feb 26
  14. 22(1):71. [CrossRef] 14. Ng GY, da Silva O, Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev. 2001
  15. CD003214. [CrossRef] 15. Sward-Comunelli SL, Mabry S